Philip C. Mack, PhD

Helping patients manage potential treatment-related adverse events is an essential part of the overall care plan in the treatment of non-small cell lung cancer. Experts provide strategies to address adverse events and best practices for providing the supportive care needed for patients.

A group of experts discuss the current treatment algorithm for NSCLC, as well as novel approaches under investigation, the impact of molecular biomarkers on their treatment decisions, and the importance of clinical trials.

Fred R. Hirsch, MD, PhD, leads a discussion with his Mount Sinai colleagues about important biomarkers found in non-small cell lung cancer, including those that provide predictive and prognostic information.

Non-small cell lung cancer experts share biomarker testing protocols and best practices for optimal outcomes, with a focus on overcoming challenges and nuances of testing.

In this video we discuss a large-scale genomic analysis that found that patterns of genetic changes detected in circulating tumor DNA mirror those identified in tumor tissue biopsies.